![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DKK2 |
Gene summary for DKK2 |
![]() |
Gene information | Species | Human | Gene symbol | DKK2 | Gene ID | 27123 |
Gene name | dickkopf WNT signaling pathway inhibitor 2 | |
Gene Alias | DKK-2 | |
Cytomap | 4q25 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9UBU2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27123 | DKK2 | S014 | Human | Liver | HCC | 7.86e-13 | 6.93e-01 | 0.2254 |
27123 | DKK2 | S015 | Human | Liver | HCC | 7.73e-03 | 3.16e-01 | 0.2375 |
27123 | DKK2 | S016 | Human | Liver | HCC | 5.17e-21 | 8.92e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
GO:003011121 | Liver | HCC | regulation of Wnt signaling pathway | 180/7958 | 328/18723 | 3.62e-06 | 4.72e-05 | 180 |
GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
GO:006082821 | Liver | HCC | regulation of canonical Wnt signaling pathway | 137/7958 | 253/18723 | 1.15e-04 | 9.70e-04 | 137 |
GO:003017721 | Liver | HCC | positive regulation of Wnt signaling pathway | 81/7958 | 140/18723 | 1.73e-04 | 1.36e-03 | 81 |
GO:009026321 | Liver | HCC | positive regulation of canonical Wnt signaling pathway | 62/7958 | 106/18723 | 6.44e-04 | 3.99e-03 | 62 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501022 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0501032 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DKK2 | SNV | Missense_Mutation | c.193G>A | p.Gly65Ser | p.G65S | Q9UBU2 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DKK2 | SNV | Missense_Mutation | rs539488952 | c.689N>A | p.Arg230His | p.R230H | Q9UBU2 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DKK2 | SNV | Missense_Mutation | novel | c.333N>A | p.His111Gln | p.H111Q | Q9UBU2 | protein_coding | tolerated(0.12) | possibly_damaging(0.873) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
DKK2 | insertion | Nonsense_Mutation | novel | c.10_11insCCATTTAACACTGTGATGCAACTGATGAAGA | p.Leu4SerfsTer3 | p.L4Sfs*3 | Q9UBU2 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
DKK2 | insertion | Frame_Shift_Ins | novel | c.27_28insAAGTA | p.Ser10LysfsTer14 | p.S10Kfs*14 | Q9UBU2 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
DKK2 | insertion | Nonsense_Mutation | novel | c.25_26insTTTTAATTTGCCTTTTCATTTGCAGCTATTGCTA | p.Asp9ValfsTer12 | p.D9Vfs*12 | Q9UBU2 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
DKK2 | insertion | Frame_Shift_Ins | novel | c.223-1_223insTTTAACAAAA | p.Ala75PhefsTer8 | p.A75Ffs*8 | Q9UBU2 | protein_coding | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
DKK2 | SNV | Missense_Mutation | c.263G>A | p.Arg88Lys | p.R88K | Q9UBU2 | protein_coding | tolerated(0.42) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
DKK2 | SNV | Missense_Mutation | novel | c.164C>T | p.Ala55Val | p.A55V | Q9UBU2 | protein_coding | tolerated(0.19) | benign(0.028) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DKK2 | SNV | Missense_Mutation | c.193N>A | p.Gly65Ser | p.G65S | Q9UBU2 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |